NCT06056791View on ClinicalTrials.gov

Study of INKmune in Patients With mCRPC (CaRe Prostate)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

August 4, 2025

Study Completion Date

November 30, 2025

Conditions
CancerMetastatic Castration-resistant Prostate CancermCRPC
Interventions
BIOLOGICAL

INKmune

INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.

Trial Locations (8)

22031

NEXT Virginia, Fairfax

45219

Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati

77380

Renovatio Clinical, The Woodlands

79915

Renovatio Clinical, El Paso

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90073

VA Greater Los Angeles Healthcare System, Los Angeles

90095

University of California, Los Angeles, Los Angeles

98108

VA Puget Sound Health Care System, Seattle

All Listed Sponsors
lead

Inmune Bio, Inc.

INDUSTRY

NCT06056791 - Study of INKmune in Patients With mCRPC (CaRe Prostate) | Biotech Hunter | Biotech Hunter